A novel platform for accelerated pharmacodynamic profiling for lead optimization of anticancer drug candidates

Journal of Biomolecular Screening

Volumn 12, Issue 2, 2007, Pages 159-166

  Szwaya, Jeffrey ^a   Bruseo, Charles ^a   Nakuci, Enkeleda ^a   McSweeney, Denise ^a   Xiang, Xiaoqin ^a,b   Senator, David ^a   France, Dennis ^a   Chen, Chang Rung ^a  

^a ARQULE INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

BRAF kinase; Cell based profiling assays; Hsp90; Infrared imager; Oncology; Western blotting

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RADICICOL; SORAFENIB;

ARTICLE; ASSAY; DATA BASE; DRUG TARGETING; ELECTROBLOTTING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGING SYSTEM; INFRARED RADIATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EVALUATION STUDIES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MELANOMA; NEOPLASMS; PHARMACOLOGY; PROTO-ONCOGENE PROTEINS B-RAF; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847644592     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106297787     Document Type: Article

References (23)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,, et al. Mutations of the BRAF gene in human cancer. Nature 2002 ; 417: 949-954.
2. Panka DJ, Atkins MB, Mier JW: Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006 ; 12: 2371-2375.
3. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A,, et al. BRAF mutation predicts sensitivity to MEK inhibition: Nature 2006 ; 439: 358-362.
4. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC,, et al. A high-affinity conformation of HSP90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003 ; 425: 407-410.
5. Georgakis GV, Younes A: Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 2005 ; 1: 273-281.
6. Pacey S, Banerji U, Judson I, Workman P: Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006 ; 172: 331-358.
7. Solit DB, Rosen N: Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006 ; 6: 1205-1214.
8. Hadden MK, Lubbers DJ, Blagg BS: Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem 2006 ; 6: 1173-1182.
9. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L: 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol Cancer Ther 2003 ; 2: 123-129.
10. Wilson CJ, Si Y, Thompsons CM, Smellie A, Ashwell MA, Liu JF,, et al. Identification of a small molecule that induces mitotic arrest using a simplified high-content screening assay and data analysis method. J Biomol Screen 2006 ; 11: 21-28.
11. Baldino CM: Perspective articles on the utility and application of solutionphase combinatorial chemistry. J Comb Chem 2000 ; 2: 89-103.
12. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose membranes: procedure and some applications. Proc Natl Acad SciUSA 1979 ; 76: 4350-4354.
13. Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005 ; 11: 1131-1138.
14. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D,, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998 ; 3: 100-108.
15. Schutz-Geschwender A, Zhang Y, Holt T, McDermitt D, Olive DM: Quantitative, two-color Western blot detection with infrared fluorescence, 2004 technical bulletin. Available at: http://www.licor.com/bio/QuantitativeWesterns/ index.jsp.
16. Hilger RA, Kredke S, Hedley D, Moeller JG, Bauer RJ, Stellberg W,, et al. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther 2002 ; 40: 567-568.
17. Panka DJ, Wang W, Atkins MB, Mier JW: The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-dependent apoptosis in melanoma cells. Cancer Res 2006 ; 66: 1611-1619.
18. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D,, et al. 17-AAG induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002 ; 8: 986-993.
19. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H,, et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 2004 ; 11: 787-797.
20. Bouzeghrane F, Reinhart DP, Reudelhuber TL, Thibault G: Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. Am J Physiol Heart Circ Physiol 2005 ; 289: H982 - H991.
21. Razidlo GL, Kortum RL, Haferbier JL, Lewis RE: Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem 2004 ; 279: 47808-47814.
22. Lee JH, Paull TT: ATM activation by DNA double-strand breaks through the MRE11-Rad50-Nbs1 complex. Science 2005 ; 308: 551-554.
23. France DS, Hughes TE, Miserendino R, Spirito JA, Babiak J, Eskesen JB,, et al. Non-immunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by non-reducing gel electrophoresis. J Lipid Res 1989 ; 30: 1997-2004.